Financhill
Sell
32

ENOV Quote, Financials, Valuation and Earnings

Last price:
$27.97
Seasonality move :
3.89%
Day range:
$28.96 - $29.87
52-week range:
$25.47 - $49.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.74x
P/B ratio:
0.83x
Volume:
622.2K
Avg. volume:
826.5K
1-year change:
-40.28%
Market cap:
$1.7B
Revenue:
$2.1B
EPS (TTM):
-$24.21

Analysts' Opinion

  • Consensus Rating
    Enovis Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $48.11, Enovis Corp. has an estimated upside of 64.31% from its current price of $29.28.
  • Price Target Downside
    According to analysts, the lowest downside price target is $33.00 representing -12.71% downside risk from its current price of $29.28.

Fair Value

  • According to the consensus of 8 analysts, Enovis Corp. has 64.31% upside to fair value with a price target of $48.11 per share.

ENOV vs. S&P 500

  • Over the past 5 trading days, Enovis Corp. has underperformed the S&P 500 by -3.79% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Enovis Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Enovis Corp. has grown year-over-year revenues for 14 quarters straight. In the most recent quarter Enovis Corp. reported revenues of $548.9M.

Earnings Growth

  • Enovis Corp. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Enovis Corp. reported earnings per share of -$9.99.
Enterprise value:
3.1B
EV / Invested capital:
0.89x
Price / LTM sales:
0.74x
EV / EBIT:
--
EV / Revenue:
1.38x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
135.52x
Price / Operating cash flow:
72.98x
Enterprise value / EBITDA:
10.97x
Gross Profit (TTM):
$1.2B
Return On Assets:
-27.78%
Net Income Margin (TTM):
-61.19%
Return On Equity:
-52.07%
Return On Invested Capital:
-33.65%
Operating Margin:
1.65%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $1.7B $2B $2.2B $505.2M $548.9M
Gross Profit $829.4M $983M $1.2B $246.4M $286.7M
Operating Income -$13.6M -$31.9M -$10.7M -$2.5M $9M
EBITDA $199.2M $235.2M $281.2M $68.7M $83.4M
Diluted EPS -$1.66 -$2.17 -$24.21 -$0.57 -$9.99
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $1.7B $1B $854.2M $1.2B $1.3B
Total Assets $8B $4.4B $4.4B $5.6B $4.4B
Current Liabilities $975.5M $853.9M $355.3M $530.2M $575.4M
Total Liabilities $3.3B $1B $959.2M $2.2B $2.4B
Total Equity $4.6B $3.4B $3.4B $3.3B $2B
Total Debt $1.8B $501.3M $444.2M $1.4B $1.4B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $30.6M $93.6M $217.1M $53.6M $82.6M
Cash From Investing -$220.2M -$957M -$224.3M -$58.4M -$56.1M
Cash From Financing $166.6M $869.7M $435K -$148K -$36.9M
Free Cash Flow -$100.4M -$61.9M $22.8M $2.4M $29.1M
ENOV
Sector
Market Cap
$1.7B
$28.4M
Price % of 52-Week High
58.85%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-0.1%
-1.32%
1-Year Price Total Return
-40.28%
-22.19%
Beta (5-Year)
1.284
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $29.68
200-day SMA
Sell
Level $32.50
Bollinger Bands (100)
Sell
Level 28.26 - 31.98
Chaikin Money Flow
Buy
Level 33.1M
20-day SMA
Sell
Level $29.49
Relative Strength Index (RSI14)
Sell
Level 46.19
ADX Line
Sell
Level 12.97
Williams %R
Neutral
Level -49.4131
50-day SMA
Sell
Level $30.58
MACD (12, 26)
Sell
Level -0.38
25-day Aroon Oscillator
Sell
Level -64
On Balance Volume
Neutral
Level 57.1M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (1.1999)
Buy
CA Score (Annual)
Level (0.3901)
Buy
Beneish M-Score (Annual)
Level (-3.445)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (0.0121)
Buy
Piotroski F Score (Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Stock Forecast FAQ

In the current month, ENOV has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ENOV average analyst price target in the past 3 months is $48.11.

  • Where Will Enovis Corp. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Enovis Corp. share price will rise to $48.11 per share over the next 12 months.

  • What Do Analysts Say About Enovis Corp.?

    Analysts are divided on their view about Enovis Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enovis Corp. is a Sell and believe this share price will drop from its current level to $33.00.

  • What Is Enovis Corp.'s Price Target?

    The price target for Enovis Corp. over the next 1-year time period is forecast to be $48.11 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is ENOV A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Enovis Corp. is a Buy. 7 of 8 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ENOV?

    You can purchase shares of Enovis Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enovis Corp. shares.

  • What Is The Enovis Corp. Share Price Today?

    Enovis Corp. was last trading at $27.97 per share. This represents the most recent stock quote for Enovis Corp.. Yesterday, Enovis Corp. closed at $29.28 per share.

  • How To Buy Enovis Corp. Stock Online?

    In order to purchase Enovis Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
51
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 61x

Buy
64
Is AAPL Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 38x

Buy
69
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Sell
47
PSTG alert for Dec 4

Pure Storage, Inc. [PSTG] is up 5.05% over the past day.

Sell
41
SMX alert for Dec 4

SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.

Sell
43
HY alert for Dec 4

Hyster-Yale, Inc. [HY] is up 1.92% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock